DrugPatentWatch Database Preview
Details for Patent: 8,598,233
Which drugs does patent 8,598,233 protect, and when does it expire?
Protection for NAMENDA XR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has fifty-seven patent family members in eighteen countries.
Summary for Patent: 8,598,233
Title: | Method for administering an NMDA receptor antagonist to a subject |
Abstract: | Compositions and methods for administering memantine to a subject are provided. In particular, a solid pharmaceutical composition in a unit dosage form for once daily oral administration is provided. The compositions comprises an extended release formulation of 22.5 mg to 33.75 mg memantine, or a pharmaceutically acceptable salt thereof, wherein administration of a dose of the composition to a human subject provides a mean plasma memantine concentration profile characterized by a change in memantine concentration as a function of time (dC/dT) that is less than 50% of the dC/dT provided by the same quantity of an immediate release form of memantine, determined in a time period between 0 hours to 6 hours after administration of memantine, and wherein dC/dT is measured in a single-dose human PK study. Methods of treating dementia, in particular Alzheimer's diseases, using the compositions are provided. |
Inventor(s): | Went; Gregory T. (Mill Valley, CA), Fultz; Timothy J. (Pleasant Hill, CA), Meyerson; Laurence R. (Las Vegas, NV) |
Assignee: | Adamas Pharmacueticals, Inc. (Emeryville, CA) |
Application Number: | 13/751,876 |
Patent Claim Types: see list of patent claims | Composition; Formulation; Dosage form; |
Drugs Protected by US Patent 8,598,233
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Forest Labs Llc | NAMENDA XR | memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022525-004 | Jun 21, 2010 | AB | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
Forest Labs Llc | NAMZARIC | donepezil hydrochloride; memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 206439-003 | Jul 18, 2016 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||||
Forest Labs Llc | NAMZARIC | donepezil hydrochloride; memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 206439-001 | Dec 23, 2014 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
Forest Labs Llc | NAMZARIC | donepezil hydrochloride; memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 206439-004 | Jul 18, 2016 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Non-Orange Book US Patents Family Members for Patent 8,598,233
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
Patent No. | Title | Estimated Patent Expiration |
---|---|---|
7,619,007 | Method and composition for administering an NMDA receptor antagonist to a subject | ➤ Sign Up |
8,058,291 | Methods and compositions for the treatment of CNS-related conditions | ➤ Sign Up |
8,168,209 | Method and composition for administering an NMDA receptor antagonist to a subject | ➤ Sign Up |
2,012,045,508 | ➤ Sign Up | |
Patent No. | Title | Estimated Patent Expiration |
International Patents Family Members for US Patent 8,598,233
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | 481096 | ➤ Sign Up | |||
Australia | 2005209310 | ➤ Sign Up | |||
Australia | 2005215767 | ➤ Sign Up | |||
Australia | 2005215775 | ➤ Sign Up | |||
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |